Home World Spain 'open' to using Russia's Covid vaccine

Clay Curtis
February 4, 2021

A dozen countries have already approved the Russian vaccine for use, including Bolivia and Argentina, where Lpez-Gatell visited in January to learn more about it. "And we need all the safe effective vaccines we can get".

Comorbidities, a known risk for Covid-19 severity, were present in about a quarter of those who entered the trial.

The study was first announced last December. It was published Tuesday in the British medical paper The Lancet.

India's regulator has approved for emergency use the AstraZeneca vaccine and another developed at home by Bharat Biotech and the state-run Indian Council of Medical Research.

Brazil, India, Kazakhstan and South Korea are now producing the jab, though not all them have made it available to the public yet.

Ukraine expects to receive shipments of Western-made vaccines soon and has prohibited the use of Russian vaccines against COVID-19, with its relations with Moscow essentially severed by the annexation of Crimea in 2014. He said one of his daughters had already received the two shots. At the same time, the European Commission confirmed it does not rule out a deal for the vaccine.

It noted that the development of the Sputnik V vaccine has been criticised for unseemly haste, corner-cutting, and an absence of transparency.

At least three more Russian coronavirus vaccines are expected to be rolled out in the coming weeks.

"Kazakhstan has made the right strategic choice in producing Russia's Sputnik V vaccine on its territory".

"Russia was right from the very beginning", he said.

More than a million people in Russian Federation have received Sputnik V, which is marketed overseas by the RDIF and has been approved for emergency use in Algeria, Argentina, Bolivia, Mexico and Serbia.

Lil Uzi Vert Has Implanted A $24 Million Diamond Into His Forehead
The hip-hop star came forward in late 2020 to call out rumored former boyfriend Lil Uzi Vert for allegedly taking one of her favorite pieces of clothing.

The study follows a phase 3 trial in Moscow hospitals and clinics that included almost 22,000 participants age 18 and older.

According to the Lancet report, 14,964 participants in the vaccine group and 4,902 in the placebo group were given two jabs 21 days apart.

Serious side effects were rare in both groups.

The authors also note that because COVID-19 cases were detected only when participants self-reported symptoms (followed by a PCR test), the efficacy analysis only includes symptomatic cases of COVID-19, and further research is needed to understand the efficacy of the vaccine on asymptomatic COVID-19, and transmission.

The study included more than 2,100 people over age 60 and the vaccine appeared to be about 92 percent effective in them. The research is continuing.

The first shot of the Russian vaccine uses a common cold-causing adenovirus to carry genes that prepare the human body to fight against COVID-19.

Mr Logunov said that the Sputnik V vaccine can be easily transported and is suitable for long storage without any special conditions. He said the two different versions of adenovirus led to higher immune response against the coronavirus.

Polly Roy is a professor of virology at the London School of Hygiene and Tropical Medicine.

Russian Federation applied last month for registration of the Sputnik V jab with the European Union through the European Medicines Agency (EMA). Hai Do was the editor.

The Associated Press reported this story.

We want to hear from you.

Other reports by

Discuss This Article

FOLLOW OUR NEWSPAPER